DRL gears up for biosimilar push, consumer health growth post record FY25
The company is likely to post double-digit revenue growth for FY26 but EBITDA margin may shrink to 25% from 28% in FY25 due to tapering sales of gRevlimid. Given this, analysts have reduced the target prices of the stock by 6-14%. Despite cuts, the target prices were 6-18% higher than the stock price on May 09 when the quarterly result was out and continue to remain above Monday's closing price of Rs1,219. Also, biosimilars and semaglutide offer future growth potential thereby supporting the stock price.
On a year-on-year basis, DRL's revenue and net profit rose 20% and 21% year-on-year to Rs8,506 crore and Rs1,587 crore in the March 2025 quarter, respectively. Excluding NRT sales, revenue growth slowed to 12%. Earnings before interest, taxes, depreciation, and amortisation (EBITDA) increased for the fifth consecutive quarter to Rs2,474.9 crore, a year-on-year 32.2% growth.
Full-year R&D investment was Rs2,738 crores, up 20% year-on-year. However, its proportion in revenue fell by 118 basis points to 8.5%. The company expects to retain the R&D expenditure in a similar range even after the gRevlimid sales normalise. It will be driven by building a differentiated pipeline spanning small molecules, biosimilars, and complex generics including peptides and cancer therapy. DRL completed 95 global generic filings, bringing the total for FY25 to 249.
The company is about to launch GLP-1 (Semaglutide) globally during the current calendar year. Abatacept, a medication used to treat rheumatoid arthritis and other autoimmune diseases, is into Phase III and the company plans to submit it for approval towards the end of 2025.
The biosimilar segment remains a key growth driver in the coming quarters. According to Axis Securities, the company's two biosimilar drugs slated for launch in Europe have the potential to contribute $40–50 million in sales in FY26. Additionally, osteoporosis drug Denosumab, scheduled for launch in FY27, is estimated to generate $50 million in annual sales. The brokerage has cut the target price to Rs1,250 from Rs1,450 earlier, valuing the company at 17 times FY27 expected earnings.
Elara Capital has lowered its FY26 earnings estimate 10% in anticipation of lower gRevlimid sales while raising FY27 estimate by 4% in anticipation of margin stability. The brokerage has highlighted price erosion in the US market and delay in product approvals as major risks to its forecast.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Standard
32 minutes ago
- Business Standard
Dr Reddys Lab gains after Q1 PAT jumps 2% YoY to Rs 1,418 cr
Dr Reddys Laboratories added 2.52% to Rs 1,279.05 after the company's consolidated net profit rose 1.8% to Rs 1,418.10 crore on 11.4% increase in revenue from operations to Rs 8,545.20 crore in Q1 FY26 over Q1 FY25. Profit before tax (PBT) stood at Rs 1,905 crore in Q1 FY26, up 1.2% YoY EBITDA for the quarter stood at Rs 2,278.4 crore, up 5.49% YoY. In its global generics business, North America contributed Rs 3,412.3 crore in revenue, a 11% year-on-year decline. Revenue from Europe surged 142% to Rs 1,274.4 crore, The India business generated revenue of Rs 1,471.1 crore, registering an 11% YoY. Revenue from Pharmaceutical Services and Active Ingredients (PSAI) came in at Rs 818.1 crore, a 7% YoY increase. Co-Chairman & MD, G V Prasad, said: "We delivered double-digit growth this quarter over the same period last year, reflecting our strength in branded markets and positive momentum in the Nicotine Replacement Therapy portfolio. The pricing pressure on Lenalidomide is expected to intensify in the U.S. generics market. We remain focused on strengthening our base business by delivery of our pipeline assets, improving overall productivity and business development." Hyderabad-based Dr. Reddys Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC.
Hans India
2 hours ago
- Hans India
Dr Reddy's net up at Rs 1,410 cr in June qtr
Hyderabad: Dr Reddy's Laboratories on Wednesday reported a 1 per cent increase in consolidated net profit to Rs1,410 crore during the June quarter. The Hyderabad-based drug major reported a net profit of Rs 1,392 crore in the year-ago period. Revenue increased to Rs8,545 crore in he period under review from Rs 7,673 crore a year earlier. "We delivered double-digit growth this quarter over the same period last year, reflecting our strength in branded markets and positive momentum in the Nicotine Replacement Therapy portfolio," Dr Reddy's Co-Chairman & MD G V Prasad said. The pricing pressure on Lenalidomide is expected to intensify in the US generics market, he noted. "We remain focused on strengthening our base business by delivery of our pipeline assets, improving overall productivity and business development," Prasad said. Shares of the company ended 0.58 per cent up at Rs1,247.55 apiece on the BSE.
New Indian Express
5 hours ago
- New Indian Express
Indian stock markets open lower on Thursday despite strong global cues
CHENNAI: Indian stock markets opened slightly lower on Thursday despite strong global cues and upbeat domestic developments. Early trade was marked by profit-booking in select IT and banking stocks, even as optimism around corporate earnings and trade deals kept broader sentiment buoyant. At the opening bell, the Sensex was down around 100 points while the Nifty slipped below the 25,250 mark. This was contrary to expectations of a mildly positive start, as indicated by GIFT Nifty futures which were trading about 60 points higher before the opening. At 9.42 AM, the Sensex dropped by another 72 points or 21% to 82,553, and Nifty fell below 25,200. Global markets offered a supportive backdrop, with Asian indices rising after the announcement of a fresh trade agreement between the US and Japan. Investors also reacted positively to news of a Free Trade Agreement (FTA) between India and the UK, signed during Prime Minister Narendra Modi's official visit to London. The deal is expected to lower tariffs on goods such as automobiles, textiles, and alcoholic beverages, and enhance market access for Indian businesses. On the domestic front, Infosys led earnings-related news after the company reported a strong first-quarter performance, raising the lower end of its FY25 revenue guidance. However, its shares traded mildly lower in early deals, reflecting cautious investor positioning. Dr Reddy's Laboratories, which reported Q1 profits slightly below market estimates due to margin pressures in the US market, and Tata Consumer Products, which saw margin pressures from rising tea and coffee input costs despite a healthy rise in net profit, were also in focus. Other companies such as Coforge, Persistent Systems, and Bajaj Housing Finance reported robust Q1 results, adding to the overall positive sentiment on corporate earnings. Despite these positives, early volatility persisted. Technical analysts pegged immediate support for Nifty in the 25,100–25,200 range, with resistance near 25,350. For the Sensex, key support was seen at 82,000 and resistance around 83,000. Foreign institutional investors remained cautious, while domestic institutional investors continued to support the markets through net buying. In the session ahead, traders will closely monitor further developments from PM Modi's UK visit, more Q1 earnings releases including from Bajaj Finance, Nestle India, and SBI Life, and any fresh cues from global markets. Outlook: The market is expected to trade in a range-bound manner in the near term, with earnings and macro developments providing direction. The India–UK FTA and global trade momentum may offer further tailwinds if supported by stable corporate performance.
